Genetic Analysis of TGFA, MTHFR, and IFR6 in Korean Patients Affected by Nonsyndromic Cleft Lip with or without Cleft Palate (CL/P)Nonsyndromic cleft lip with or without cleft palate (CL/P) is a common craniofacial birth defect that is the result of a mixture of genetic and environmental factors.
('Genetic', 'Genetic', 'JJ', 'B-NP', 'O')
('Analysis', 'Analysis', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('TGFA,', 'TGFA,', 'NN', 'B-NP', 'B-protein')
('MTHFR,', 'MTHFR,', 'NN', 'I-NP', 'I-protein')
('and', 'and', 'CC', 'I-NP', 'O')
('IFR6', 'IFR6', 'NN', 'I-NP', 'B-protein')
('in', 'in', 'IN', 'B-PP', 'O')
('Korean', 'Korean', 'JJ', 'B-NP', 'O')
('Patients', 'Patient', 'NNS', 'I-NP', 'O')
('Affected', 'Affect', 'VBN', 'B-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('Nonsyndromic', 'Nonsyndromic', 'JJ', 'B-NP', 'O')
('Cleft', 'Cleft', 'NN', 'I-NP', 'O')
('Lip', 'Lip', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('or', 'or', 'CC', 'B-PP', 'O')
('without', 'without', 'IN', 'B-PP', 'O')
('Cleft', 'Cleft', 'NNP', 'B-NP', 'O')
('Palate', 'Palate', 'NNP', 'I-NP', 'O')
('(CL/P)', '(CL/P)', 'NNP', 'I-NP', 'O')
('Nonsyndromic', 'Nonsyndromic', 'JJ', 'I-NP', 'O')
('cleft', 'cleft', 'NN', 'I-NP', 'O')
('lip', 'lip', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('or', 'or', 'CC', 'B-PP', 'O')
('without', 'without', 'IN', 'B-PP', 'O')
('cleft', 'cleft', 'NN', 'B-NP', 'O')
('palate', 'palate', 'NN', 'I-NP', 'O')
('(CL/P)', '(CL/P)', 'NN', 'I-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('common', 'common', 'JJ', 'I-NP', 'O')
('craniofacial', 'craniofacial', 'JJ', 'I-NP', 'O')
('birth', 'birth', 'NN', 'I-NP', 'O')
('defect', 'defect', 'NN', 'I-NP', 'O')
('that', 'that', 'WDT', 'B-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('result', 'result', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('mixture', 'mixture', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('genetic', 'genetic', 'JJ', 'B-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('environmental', 'environmental', 'JJ', 'I-NP', 'O')
('factors.', 'factors.', 'NNS', 'I-NP', 'O')
While studies have identified a number of different candidate genes and loci for the etiology of CL/P, the results have not been consistent among different ethnic groups.
('While', 'While', 'IN', 'B-SBAR', 'O')
('studies', 'study', 'NNS', 'B-NP', 'O')
('have', 'have', 'VBP', 'B-VP', 'O')
('identified', 'identify', 'VBN', 'I-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('number', 'number', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('different', 'different', 'JJ', 'B-NP', 'O')
('candidate', 'candidate', 'NN', 'I-NP', 'B-DNA')
('genes', 'gene', 'NNS', 'I-NP', 'I-DNA')
('and', 'and', 'CC', 'I-NP', 'O')
('loci', 'locus', 'NNS', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('etiology', 'etiology', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('CL/P,', 'CL/P,', 'NN', 'B-NP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('results', 'result', 'NNS', 'I-NP', 'O')
('have', 'have', 'VBP', 'B-VP', 'O')
('not', 'not', 'RB', 'I-VP', 'O')
('been', 'be', 'VBN', 'I-VP', 'O')
('consistent', 'consistent', 'JJ', 'B-ADJP', 'O')
('among', 'among', 'IN', 'B-PP', 'O')
('different', 'different', 'JJ', 'B-NP', 'O')
('ethnic', 'ethnic', 'JJ', 'I-NP', 'O')
('groups.', 'groups.', 'NNS', 'I-NP', 'O')
To study the genetic association of the candidate genes in Korean patients affected by CL/P, we genotyped 97 nonsyndromic CL/P patients and 100 control individuals using single nucleotide polymorphic markers at the MTHFR , TGFA , and IRF6 genes.
('To', 'To', 'TO', 'B-VP', 'O')
('study', 'study', 'VB', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('genetic', 'genetic', 'JJ', 'I-NP', 'O')
('association', 'association', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('candidate', 'candidate', 'NN', 'I-NP', 'B-DNA')
('genes', 'gene', 'NNS', 'I-NP', 'I-DNA')
('in', 'in', 'IN', 'B-PP', 'O')
('Korean', 'Korean', 'JJ', 'B-NP', 'O')
('patients', 'patient', 'NNS', 'I-NP', 'O')
('affected', 'affect', 'VBN', 'B-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('CL/P,', 'CL/P,', 'NN', 'B-NP', 'B-protein')
('we', 'we', 'PRP', 'B-NP', 'O')
('genotyped', 'genotype', 'VBD', 'B-VP', 'O')
('97', '97', 'CD', 'B-NP', 'O')
('nonsyndromic', 'nonsyndromic', 'JJ', 'I-NP', 'O')
('CL/P', 'CL/P', 'NN', 'I-NP', 'O')
('patients', 'patient', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('100', '100', 'CD', 'B-NP', 'O')
('control', 'control', 'NN', 'I-NP', 'O')
('individuals', 'individual', 'NNS', 'I-NP', 'O')
('using', 'use', 'VBG', 'B-VP', 'O')
('single', 'single', 'JJ', 'B-NP', 'O')
('nucleotide', 'nucleotide', 'NN', 'I-NP', 'O')
('polymorphic', 'polymorphic', 'JJ', 'I-NP', 'O')
('markers', 'marker', 'NNS', 'I-NP', 'O')
('at', 'at', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('MTHFR', 'MTHFR', 'NN', 'I-NP', 'B-protein')
(',', ',', ',', 'O', 'O')
('TGFA', 'TGFA', 'NN', 'B-NP', 'B-protein')
(',', ',', ',', 'O', 'O')
('and', 'and', 'CC', 'O', 'O')
('IRF6', 'IRF6', 'NN', 'B-NP', 'B-protein')
('genes.', 'genes.', 'NNS', 'I-NP', 'O')
We report that the T3827C marker at TGFA showed significant association with nonsyndromic CL/P, but all the other markers tested were not significantly associated with nonsyndromic CL/P in Korean patients.
('We', 'We', 'PRP', 'B-NP', 'O')
('report', 'report', 'VBP', 'B-VP', 'O')
('that', 'that', 'IN', 'B-SBAR', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('T3827C', 'T3827C', 'NN', 'I-NP', 'B-protein')
('marker', 'marker', 'NN', 'I-NP', 'I-protein')
('at', 'at', 'IN', 'B-PP', 'O')
('TGFA', 'TGFA', 'NN', 'B-NP', 'B-protein')
('showed', 'show', 'VBD', 'B-VP', 'O')
('significant', 'significant', 'JJ', 'B-NP', 'O')
('association', 'association', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('nonsyndromic', 'nonsyndromic', 'JJ', 'B-NP', 'O')
('CL/P,', 'CL/P,', 'NN', 'I-NP', 'O')
('but', 'but', 'CC', 'O', 'O')
('all', 'all', 'PDT', 'B-NP', 'O')
('the', 'the', 'DT', 'I-NP', 'O')
('other', 'other', 'JJ', 'I-NP', 'O')
('markers', 'marker', 'NNS', 'I-NP', 'O')
('tested', 'test', 'VBN', 'B-VP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('not', 'not', 'RB', 'I-VP', 'O')
('significantly', 'significantly', 'RB', 'I-VP', 'O')
('associated', 'associate', 'VBN', 'I-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('nonsyndromic', 'nonsyndromic', 'JJ', 'B-NP', 'O')
('CL/P', 'CL/P', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('Korean', 'Korean', 'JJ', 'B-NP', 'O')
('patients.', 'patients.', 'NNS', 'I-NP', 'O')
Cleft lip with or without cleft palate (CL/P) is the most common craniofacial birth defect with an average prevalence of 1 in 500 to 1 in 2,500 births (Tolarova et al ., 1998).
('Cleft', 'Cleft', 'NN', 'B-NP', 'O')
('lip', 'lip', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('or', 'or', 'CC', 'B-PP', 'O')
('without', 'without', 'IN', 'B-PP', 'O')
('cleft', 'cleft', 'NN', 'B-NP', 'O')
('palate', 'palate', 'NN', 'I-NP', 'O')
('(CL/P)', '(CL/P)', 'NN', 'I-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('most', 'most', 'RBS', 'I-NP', 'O')
('common', 'common', 'JJ', 'I-NP', 'O')
('craniofacial', 'craniofacial', 'JJ', 'I-NP', 'O')
('birth', 'birth', 'NN', 'I-NP', 'O')
('defect', 'defect', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('average', 'average', 'JJ', 'I-NP', 'O')
('prevalence', 'prevalence', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('1', '1', 'CD', 'B-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('500', '500', 'CD', 'B-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('1', '1', 'CD', 'B-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('2,500', '2,500', 'CD', 'B-NP', 'O')
('births', 'birth', 'NNS', 'I-NP', 'O')
('(Tolarova', '(Tolarova', 'NNP', 'B-NP', 'O')
('et', 'et', 'FW', 'I-NP', 'O')
('al', 'al', 'FW', 'I-NP', 'O')
('.,', '.,', 'VBD', 'B-VP', 'O')
('1998).', '1998).', 'CD', 'B-NP', 'O')
The incidence of CL/P significantly varies with different ethnic groups, geographic locations and socioeconomic status.
('The', 'The', 'DT', 'B-NP', 'O')
('incidence', 'incidence', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('CL/P', 'CL/P', 'NN', 'B-NP', 'B-protein')
('significantly', 'significantly', 'RB', 'B-ADVP', 'O')
('varies', 'vary', 'VBZ', 'B-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('different', 'different', 'JJ', 'B-NP', 'O')
('ethnic', 'ethnic', 'JJ', 'I-NP', 'O')
('groups,', 'groups,', 'NN', 'I-NP', 'O')
('geographic', 'geographic', 'JJ', 'I-NP', 'O')
('locations', 'location', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('socioeconomic', 'socioeconomic', 'JJ', 'B-NP', 'O')
('status.', 'status.', 'NNS', 'I-NP', 'O')
African Americans exhibit the lowest prevalence of 0.3 in 1,000 births, followed by Caucasians with prevalence of 1 in 1000 births (Wyszynski et al ., 1996).
('African', 'African', 'JJ', 'B-NP', 'O')
('Americans', 'American', 'NNPS', 'I-NP', 'O')
('exhibit', 'exhibit', 'VBP', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('lowest', 'low', 'JJS', 'I-NP', 'O')
('prevalence', 'prevalence', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('0.3', '0.3', 'CD', 'B-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('1,000', '1,000', 'CD', 'B-NP', 'O')
('births,', 'births,', 'NN', 'I-NP', 'O')
('followed', 'follow', 'VBN', 'B-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('Caucasians', 'Caucasian', 'NNS', 'B-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('prevalence', 'prevalence', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('1', '1', 'CD', 'B-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('1000', '1000', 'CD', 'B-NP', 'O')
('births', 'birth', 'NNS', 'I-NP', 'O')
('(Wyszynski', '(Wyszynski', 'NNP', 'B-NP', 'O')
('et', 'et', 'FW', 'I-NP', 'O')
('al', 'al', 'FW', 'I-NP', 'O')
('.,', '.,', 'IN', 'B-PP', 'O')
('1996).', '1996).', 'CD', 'B-NP', 'O')
In contrast, Asians and NativeAmericans show the highest prevalence of 2.1 and 3.6 in 1,000 births, respectively (Wyszynski et al ., 1996).
('In', 'In', 'IN', 'B-PP', 'O')
('contrast,', 'contrast,', 'NN', 'B-NP', 'O')
('Asians', 'Asian', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('Native', 'Native', 'JJ', 'B-NP', 'O')
('Americans', 'American', 'NNPS', 'I-NP', 'O')
('show', 'show', 'VBP', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('highest', 'high', 'JJS', 'I-NP', 'O')
('prevalence', 'prevalence', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('2.1', '2.1', 'CD', 'B-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('3.6', '3.6', 'CD', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('1,000', '1,000', 'CD', 'B-NP', 'O')
('births,', 'births,', 'NN', 'I-NP', 'O')
('respectively', 'respectively', 'RB', 'B-ADVP', 'O')
('(Wyszynski', '(Wyszynski', 'NNP', 'B-NP', 'O')
('et', 'et', 'FW', 'I-NP', 'O')
('al', 'al', 'FW', 'I-NP', 'O')
('.,', '.,', 'IN', 'B-PP', 'O')
('1996).', '1996).', 'CD', 'B-NP', 'O')
CL/P is epidemiologically and etiologically distinct from isolated cleft palate (CP) which shows an ethnic heterogeneity of incidence that is distinct from CL/P (Jones, 1993).
('CL/P', 'CL/P', 'NN', 'B-NP', 'B-protein')
('is', 'be', 'VBZ', 'B-VP', 'O')
('epidemiologically', 'epidemiologically', 'RB', 'B-ADVP', 'O')
('and', 'and', 'CC', 'O', 'O')
('etiologically', 'etiologically', 'RB', 'B-ADJP', 'O')
('distinct', 'distinct', 'JJ', 'I-ADJP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('isolated', 'isolate', 'VBN', 'B-NP', 'O')
('cleft', 'cleft', 'NN', 'I-NP', 'O')
('palate', 'palate', 'NN', 'I-NP', 'O')
('(CP)', '(CP)', 'NN', 'I-NP', 'O')
('which', 'which', 'WDT', 'B-NP', 'O')
('shows', 'show', 'VBZ', 'B-VP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('ethnic', 'ethnic', 'JJ', 'I-NP', 'O')
('heterogeneity', 'heterogeneity', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('incidence', 'incidence', 'NN', 'B-NP', 'O')
('that', 'that', 'WDT', 'B-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('distinct', 'distinct', 'JJ', 'B-ADJP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('CL/P', 'CL/P', 'NN', 'B-NP', 'O')
('(Jones,', '(Jones,', 'NN', 'I-NP', 'O')
('1993).', '1993).', 'CD', 'I-NP', 'O')
Orofacial clefting also occurs as a characteristic clinical feature in syndromic cases, such as Van der Woude syndrome, cleft palate with ankyloglossia, and Treacher-Collins syndrome (Stainier et al ., 2004).
('Orofacial', 'Orofacial', 'JJ', 'B-NP', 'O')
('clefting', 'clefting', 'NN', 'I-NP', 'O')
('also', 'also', 'RB', 'B-ADVP', 'O')
('occurs', 'occur', 'VBZ', 'B-VP', 'O')
('as', 'as', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('characteristic', 'characteristic', 'JJ', 'I-NP', 'O')
('clinical', 'clinical', 'JJ', 'I-NP', 'O')
('feature', 'feature', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('syndromic', 'syndromic', 'JJ', 'B-NP', 'O')
('cases,', 'cases,', 'NN', 'I-NP', 'O')
('such', 'such', 'JJ', 'B-PP', 'O')
('as', 'as', 'IN', 'I-PP', 'O')
('Van', 'Van', 'NNP', 'B-NP', 'O')
('der', 'der', 'NNP', 'I-NP', 'O')
('Woude', 'Woude', 'NNP', 'I-NP', 'O')
('syndrome,', 'syndrome,', 'NN', 'I-NP', 'O')
('cleft', 'cleave', 'VBD', 'B-VP', 'O')
('palate', 'palate', 'NN', 'B-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('ankyloglossia,', 'ankyloglossia,', 'NN', 'B-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('Treacher-Collins', 'Treacher-Collins', 'JJ', 'B-NP', 'O')
('syndrome', 'syndrome', 'NN', 'I-NP', 'O')
('(Stainier', '(Stainier', 'NNP', 'I-NP', 'O')
('et', 'et', 'FW', 'I-NP', 'O')
('al', 'al', 'FW', 'I-NP', 'O')
('.,', '.,', 'VBD', 'B-VP', 'O')
('2004).', '2004).', 'CD', 'B-NP', 'O')
However, most cases of orofacial clefting are nonsyndromic, showing no association with other structural abnormalities.
('However,', 'However,', 'WRB', 'B-ADVP', 'O')
('most', 'most', 'JJS', 'B-NP', 'O')
('cases', 'case', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('orofacial', 'orofacial', 'JJ', 'B-NP', 'O')
('clefting', 'clefting', 'NN', 'I-NP', 'O')
('are', 'be', 'VBP', 'B-VP', 'O')
('nonsyndromic,', 'nonsyndromic,', 'JJ', 'B-ADJP', 'O')
('showing', 'show', 'VBG', 'B-VP', 'O')
('no', 'no', 'DT', 'B-NP', 'O')
('association', 'association', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('other', 'other', 'JJ', 'B-NP', 'O')
('structural', 'structural', 'JJ', 'I-NP', 'O')
('abnormalities.', 'abnormalities.', 'NN', 'I-NP', 'O')
Nonsyndromic CL/P is a genetically and developmentally complex disorder, with a mutifactorial etiology that encompasses genetic and environmental components.
('Nonsyndromic', 'Nonsyndromic', 'JJ', 'B-NP', 'B-protein')
('CL/P', 'CL/P', 'NN', 'I-NP', 'I-protein')
('is', 'be', 'VBZ', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('genetically', 'genetically', 'RB', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('developmentally', 'developmentally', 'RB', 'I-NP', 'O')
('complex', 'complex', 'JJ', 'I-NP', 'O')
('disorder,', 'disorder,', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('mutifactorial', 'mutifactorial', 'JJ', 'I-NP', 'O')
('etiology', 'etiology', 'NN', 'I-NP', 'O')
('that', 'that', 'WDT', 'B-NP', 'O')
('encompasses', 'encompass', 'VBZ', 'B-VP', 'O')
('genetic', 'genetic', 'JJ', 'B-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('environmental', 'environmental', 'JJ', 'I-NP', 'O')
('components.', 'components.', 'NN', 'I-NP', 'O')
Palatal developmental is an elaborately controlled process involving a number of different factors including growth factors, transcription factors, receptors, cell adhesion proteins, extracellular matrix proteins, and matrix metalloproteinases (Stainier et al ., 2004).
('Palatal', 'Palatal', 'JJ', 'B-NP', 'O')
('developmental', 'developmental', 'JJ', 'I-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('elaborately', 'elaborately', 'RB', 'I-NP', 'O')
('controlled', 'control', 'VBN', 'I-NP', 'O')
('process', 'process', 'NN', 'I-NP', 'O')
('involving', 'involve', 'VBG', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('number', 'number', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('different', 'different', 'JJ', 'B-NP', 'O')
('factors', 'factor', 'NNS', 'I-NP', 'O')
('including', 'include', 'VBG', 'B-PP', 'O')
('growth', 'growth', 'NN', 'B-NP', 'O')
('factors,', 'factors,', 'NN', 'I-NP', 'O')
('transcription', 'transcription', 'NN', 'I-NP', 'O')
('factors,', 'factors,', 'NN', 'I-NP', 'O')
('receptors,', 'receptors,', 'NN', 'I-NP', 'O')
('cell', 'cell', 'NN', 'I-NP', 'O')
('adhesion', 'adhesion', 'NN', 'I-NP', 'O')
('proteins,', 'proteins,', 'NN', 'I-NP', 'O')
('extracellular', 'extracellular', 'JJ', 'I-NP', 'O')
('matrix', 'matrix', 'NN', 'I-NP', 'O')
('proteins,', 'proteins,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('matrix', 'matrix', 'NN', 'I-NP', 'B-protein')
('metalloproteinases', 'metalloproteinas', 'NNS', 'I-NP', 'I-protein')
('(Stainier', '(Stainier', 'NNP', 'I-NP', 'O')
('et', 'et', 'FW', 'I-NP', 'O')
('al', 'al', 'FW', 'I-NP', 'O')
('.,', '.,', 'VBD', 'B-VP', 'O')
('2004).', '2004).', 'CD', 'B-NP', 'O')
A number of genes, including TGFA (transforming growth factor alpha), TGFB2 (transforming growth factor beta 2), TGFB3 (transforming growth factor beta 3), IRF6 (interferon regulatory factor 6), MSX1 (muscle segment homeobox Drosophila homolog 1), and MTHFR (methylenetetrahydrofolate reductase), have been reported in association studies with nonsyndromic CL/P (Cobourne, 2004; Jugessur et al ., 2005).
('A', 'A', 'DT', 'B-NP', 'O')
('number', 'number', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('genes,', 'genes,', 'NN', 'B-NP', 'O')
('including', 'include', 'VBG', 'B-PP', 'O')
('TGFA', 'TGFA', 'NN', 'B-NP', 'B-protein')
('(transforming', '(transforme', 'VBG', 'B-VP', 'I-protein')
('growth', 'growth', 'NN', 'B-NP', 'I-protein')
('factor', 'factor', 'NN', 'I-NP', 'I-protein')
('alpha),', 'alpha),', 'NN', 'I-NP', 'I-protein')
('TGFB2', 'TGFB2', 'NN', 'I-NP', 'I-protein')
('(transforming', '(transforme', 'VBG', 'B-VP', 'I-protein')
('growth', 'growth', 'NN', 'B-NP', 'I-protein')
('factor', 'factor', 'NN', 'I-NP', 'I-protein')
('beta', 'beta', 'SYM', 'B-NP', 'I-protein')
('2),', '2),', 'NN', 'I-NP', 'I-protein')
('TGFB3', 'TGFB3', 'NN', 'I-NP', 'I-protein')
('(transforming', '(transforme', 'VBG', 'B-VP', 'I-protein')
('growth', 'growth', 'NN', 'B-NP', 'I-protein')
('factor', 'factor', 'NN', 'I-NP', 'I-protein')
('beta', 'beta', 'SYM', 'B-NP', 'I-protein')
('3),', '3),', 'CD', 'I-NP', 'I-protein')
('IRF6', 'IRF6', 'NN', 'I-NP', 'I-protein')
('(interferon', '(interferon', 'NN', 'I-NP', 'I-protein')
('regulatory', 'regulatory', 'JJ', 'I-NP', 'I-protein')
('factor', 'factor', 'NN', 'I-NP', 'I-protein')
('6),', '6),', 'CD', 'I-NP', 'I-protein')
('MSX1', 'MSX1', 'NN', 'I-NP', 'I-protein')
('(muscle', '(muscle', 'NN', 'I-NP', 'I-protein')
('segment', 'segment', 'NN', 'I-NP', 'I-protein')
('homeobox', 'homeobox', 'NN', 'I-NP', 'I-protein')
('Drosophila', 'Drosophila', 'FW', 'I-NP', 'I-protein')
('homolog', 'homolog', 'NN', 'I-NP', 'I-protein')
('1),', '1),', 'NN', 'I-NP', 'I-protein')
('and', 'and', 'CC', 'I-NP', 'O')
('MTHFR', 'MTHFR', 'NN', 'I-NP', 'B-protein')
('(methylenetetrahydrofolate', '(methylenetetrahydrofolate', 'VBP', 'B-VP', 'O')
('reductase),', 'reductase),', 'NN', 'B-NP', 'O')
('have', 'have', 'VBP', 'B-VP', 'O')
('been', 'be', 'VBN', 'I-VP', 'O')
('reported', 'report', 'VBN', 'I-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('association', 'association', 'NN', 'B-NP', 'O')
('studies', 'study', 'NNS', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('nonsyndromic', 'nonsyndromic', 'JJ', 'B-NP', 'O')
('CL/P', 'CL/P', 'NN', 'I-NP', 'O')
('(Cobourne,', '(Cobourne,', 'NNP', 'I-NP', 'O')
('2004;', '2004;', ':', 'O', 'O')
('Jugessur', 'Jugessur', 'NNP', 'B-NP', 'O')
('et', 'et', 'FW', 'B-NP', 'O')
('al', 'al', 'FW', 'I-NP', 'O')
('.,', '.,', 'VBD', 'B-VP', 'O')
('2005).', '2005).', 'CD', 'B-NP', 'O')
The epigenetic influence of environmental factors such as folate deficiency, steroid and statin use, retinoid exposure, maternal smoking, and maternal alcohol use are also associated with the incidence of CL/P (Cobourne, 2004; Jugessur et al ., 2005).
('The', 'The', 'DT', 'B-NP', 'O')
('epigenetic', 'epigenetic', 'JJ', 'I-NP', 'O')
('influence', 'influence', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('environmental', 'environmental', 'JJ', 'B-NP', 'B-protein')
('factors', 'factor', 'NNS', 'I-NP', 'I-protein')
('such', 'such', 'JJ', 'B-PP', 'O')
('as', 'as', 'IN', 'I-PP', 'O')
('folate', 'folate', 'JJ', 'B-NP', 'O')
('deficiency,', 'deficiency,', 'NN', 'I-NP', 'O')
('steroid', 'steroid', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('statin', 'statin', 'NN', 'B-NP', 'O')
('use,', 'use,', 'NN', 'I-NP', 'O')
('retinoid', 'retinoid', 'NN', 'I-NP', 'O')
('exposure,', 'exposure,', 'NN', 'I-NP', 'O')
('maternal', 'maternal', 'JJ', 'I-NP', 'O')
('smoking,', 'smoking,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('maternal', 'maternal', 'JJ', 'B-NP', 'O')
('alcohol', 'alcohol', 'NN', 'I-NP', 'O')
('use', 'use', 'NN', 'I-NP', 'O')
('are', 'be', 'VBP', 'B-VP', 'O')
('also', 'also', 'RB', 'I-VP', 'O')
('associated', 'associate', 'VBN', 'I-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('incidence', 'incidence', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('CL/P', 'CL/P', 'NNP', 'B-NP', 'O')
('(Cobourne,', '(Cobourne,', 'NNP', 'I-NP', 'O')
('2004;', '2004;', ':', 'O', 'O')
('Jugessur', 'Jugessur', 'NNP', 'B-NP', 'O')
('et', 'et', 'FW', 'B-NP', 'O')
('al', 'al', 'FW', 'I-NP', 'O')
('.,', '.,', 'VBD', 'B-VP', 'O')
('2005).', '2005).', 'CD', 'B-NP', 'O')
In an attempt to re-examine association of MTHFR , TGFA , and IRF6 with nonsyndromic CL/P in Korean patients, we genotyped 97 nonsyndromic CL/P patients with the MTHFR -C677T, TGFA -C3296T, TGFA -T3827C and IRF6 -G820A markers.
('In', 'In', 'IN', 'B-PP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('attempt', 'attempt', 'NN', 'I-NP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('re-examine', 're-examine', 'VB', 'I-VP', 'O')
('association', 'association', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('MTHFR', 'MTHFR', 'NN', 'B-NP', 'B-protein')
(',', ',', ',', 'O', 'O')
('TGFA', 'TGFA', 'NN', 'B-NP', 'B-protein')
(',', ',', ',', 'O', 'O')
('and', 'and', 'CC', 'O', 'O')
('IRF6', 'IRF6', 'NN', 'B-NP', 'B-protein')
('with', 'with', 'IN', 'B-PP', 'O')
('nonsyndromic', 'nonsyndromic', 'JJ', 'B-NP', 'O')
('CL/P', 'CL/P', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('Korean', 'Korean', 'JJ', 'B-NP', 'O')
('patients,', 'patients,', 'NN', 'I-NP', 'O')
('we', 'we', 'PRP', 'B-NP', 'O')
('genotyped', 'genotype', 'VBD', 'B-VP', 'O')
('97', '97', 'CD', 'B-NP', 'O')
('nonsyndromic', 'nonsyndromic', 'JJ', 'I-NP', 'O')
('CL/P', 'CL/P', 'NN', 'I-NP', 'O')
('patients', 'patient', 'NNS', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('MTHFR', 'MTHFR', 'NN', 'I-NP', 'B-protein')
('-C677T,', '-C677T,', 'NN', 'I-NP', 'O')
('TGFA', 'TGFA', 'NN', 'I-NP', 'O')
('-C3296T,', '-C3296T,', 'NN', 'I-NP', 'O')
('TGFA', 'TGFA', 'NN', 'I-NP', 'O')
('-T3827C', '-T3827C', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('IRF6', 'IRF6', 'NN', 'B-NP', 'B-protein')
('-G820A', '-G820A', 'NN', 'I-NP', 'O')
('markers.', 'markers.', 'NNS', 'I-NP', 'O')
In these studies, TGFA -T3827C showed significant association with nonsyndromic CL/P, but the other markers were not significantly associated with nonsyndromic CL/P in Korean patients.
('In', 'In', 'IN', 'B-PP', 'O')
('these', 'these', 'DT', 'B-NP', 'O')
('studies,', 'studies,', 'NN', 'I-NP', 'O')
('TGFA', 'TGFA', 'NN', 'I-NP', 'O')
('-T3827C', '-T3827C', 'NN', 'I-NP', 'O')
('showed', 'show', 'VBD', 'B-VP', 'O')
('significant', 'significant', 'JJ', 'B-NP', 'O')
('association', 'association', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('nonsyndromic', 'nonsyndromic', 'JJ', 'B-NP', 'O')
('CL/P,', 'CL/P,', 'NN', 'I-NP', 'O')
('but', 'but', 'CC', 'O', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('other', 'other', 'JJ', 'I-NP', 'O')
('markers', 'marker', 'NNS', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('not', 'not', 'RB', 'I-VP', 'O')
('significantly', 'significantly', 'RB', 'I-VP', 'O')
('associated', 'associate', 'VBN', 'I-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('nonsyndromic', 'nonsyndromic', 'JJ', 'B-NP', 'O')
('CL/P', 'CL/P', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('Korean', 'Korean', 'JJ', 'B-NP', 'O')
('patients.', 'patients.', 'NNS', 'I-NP', 'O')
The study group consisted of 97 Korean patients withnonsyndromic CL/P and 100 non-related healthy individuals.
('The', 'The', 'DT', 'B-NP', 'O')
('study', 'study', 'NN', 'I-NP', 'O')
('group', 'group', 'NN', 'I-NP', 'O')
('consisted', 'consist', 'VBD', 'B-VP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('97', '97', 'CD', 'B-NP', 'O')
('Korean', 'Korean', 'JJ', 'I-NP', 'O')
('patients', 'patient', 'NNS', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('nonsyndromic', 'nonsyndromic', 'JJ', 'B-NP', 'O')
('CL/P', 'CL/P', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('100', '100', 'CD', 'B-NP', 'O')
('non-related', 'non-related', 'JJ', 'I-NP', 'O')
('healthy', 'healthy', 'JJ', 'I-NP', 'O')
('individuals.', 'individuals.', 'NNS', 'I-NP', 'O')
The CL/P phenotype spectrum included unilateral or bilateral cleft lip with or without cleft palate.
('The', 'The', 'DT', 'B-NP', 'O')
('CL/P', 'CL/P', 'NN', 'I-NP', 'O')
('phenotype', 'phenotype', 'NN', 'I-NP', 'O')
('spectrum', 'spectrum', 'NN', 'I-NP', 'O')
('included', 'include', 'VBD', 'B-VP', 'O')
('unilateral', 'unilateral', 'JJ', 'B-NP', 'O')
('or', 'or', 'CC', 'I-NP', 'O')
('bilateral', 'bilateral', 'JJ', 'I-NP', 'O')
('cleft', 'cleft', 'NN', 'I-NP', 'O')
('lip', 'lip', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('or', 'or', 'CC', 'B-PP', 'O')
('without', 'without', 'IN', 'B-PP', 'O')
('cleft', 'cleft', 'NN', 'B-NP', 'O')
('palate.', 'palate.', 'NN', 'I-NP', 'O')
Some of the patients also showed bifid uvula.
('Some', 'Some', 'DT', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('patients', 'patient', 'NNS', 'I-NP', 'O')
('also', 'also', 'RB', 'B-ADVP', 'O')
('showed', 'show', 'VBD', 'B-VP', 'O')
('bifid', 'bifid', 'JJ', 'B-NP', 'O')
('uvula.', 'uvula.', 'NN', 'I-NP', 'O')
After informed consent was obtained from patients and control individuals, blood samples were taken to be used in the study.
('After', 'After', 'IN', 'B-PP', 'O')
('informed', 'inform', 'VBN', 'B-NP', 'O')
('consent', 'consent', 'NN', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('obtained', 'obtain', 'VBN', 'I-VP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('patients', 'patient', 'NNS', 'B-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('control', 'control', 'NN', 'B-NP', 'O')
('individuals,', 'individuals,', 'NN', 'I-NP', 'O')
('blood', 'blood', 'NN', 'I-NP', 'O')
('samples', 'sample', 'NNS', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('taken', 'take', 'VBN', 'I-VP', 'O')
('to', 'to', 'TO', 'I-VP', 'O')
('be', 'be', 'VB', 'I-VP', 'O')
('used', 'use', 'VBN', 'I-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('study.', 'study.', 'NN', 'I-NP', 'O')
Genomic DNA samples of the participating individuals were extracted from whole blood using a Puregene DNA Isolation Kit according to the manufacturer’s protocol (Gentra Systems).
('Genomic', 'Genomic', 'JJ', 'B-NP', 'O')
('DNA', 'DNA', 'NN', 'I-NP', 'O')
('samples', 'sample', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('participating', 'participate', 'VBG', 'I-NP', 'O')
('individuals', 'individual', 'NNS', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('extracted', 'extract', 'VBN', 'I-VP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('whole', 'whole', 'JJ', 'B-NP', 'O')
('blood', 'blood', 'NN', 'I-NP', 'O')
('using', 'use', 'VBG', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('Puregene', 'Puregene', 'NN', 'I-NP', 'O')
('DNA', 'DNA', 'NN', 'I-NP', 'O')
('Isolation', 'Isolation', 'NN', 'I-NP', 'O')
('Kit', 'Kit', 'NN', 'I-NP', 'O')
('according', 'accord', 'VBG', 'B-PP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('manufacturer’s', 'manufacturer’', 'NNS', 'I-NP', 'O')
('protocol', 'protocol', 'NN', 'I-NP', 'O')
('(Gentra', '(Gentra', 'NNP', 'I-NP', 'O')
('Systems).', 'Systems).', 'NNP', 'I-NP', 'O')
The genomic regions encompassing MTHFR -C677T, TGFA -C3296T, TGFA -T3827C, and IRF6 -G820A were PCR-amplified using primers derived from the flanking sequences of each marker.
('The', 'The', 'DT', 'B-NP', 'O')
('genomic', 'genomic', 'JJ', 'I-NP', 'B-DNA')
('regions', 'region', 'NNS', 'I-NP', 'I-DNA')
('encompassing', 'encompass', 'VBG', 'B-VP', 'O')
('MTHFR', 'MTHFR', 'NN', 'B-NP', 'B-protein')
('-C677T,', '-C677T,', 'NN', 'I-NP', 'O')
('TGFA', 'TGFA', 'NN', 'I-NP', 'O')
('-C3296T,', '-C3296T,', 'NN', 'I-NP', 'O')
('TGFA', 'TGFA', 'NN', 'I-NP', 'O')
('-T3827C,', '-T3827C,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('IRF6', 'IRF6', 'NN', 'B-NP', 'B-protein')
('-G820A', '-G820A', 'NN', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('PCR-amplified', 'PCR-amplified', 'JJ', 'B-NP', 'O')
('using', 'use', 'VBG', 'I-NP', 'O')
('primers', 'primer', 'NNS', 'I-NP', 'O')
('derived', 'derive', 'VBN', 'B-VP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('flanking', 'flanking', 'NN', 'I-NP', 'B-DNA')
('sequences', 'sequence', 'NNS', 'I-NP', 'I-DNA')
('of', 'of', 'IN', 'B-PP', 'O')
('each', 'each', 'DT', 'B-NP', 'O')
('marker.', 'marker.', 'NN', 'I-NP', 'O')
The sequences of the primers are listed in Table 1.
('The', 'The', 'DT', 'B-NP', 'O')
('sequences', 'sequence', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('primers', 'primer', 'NNS', 'I-NP', 'O')
('are', 'be', 'VBP', 'B-VP', 'O')
('listed', 'list', 'VBN', 'I-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('Table', 'Table', 'JJ', 'B-NP', 'O')
('1.', '1.', 'CD', 'I-NP', 'O')
Thermocycling was performed using Taq polymerase (Promega) according to the manufacturer’s instructions.
('Thermocycling', 'Thermocycle', 'VBG', 'B-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('performed', 'perform', 'VBN', 'I-VP', 'O')
('using', 'use', 'VBG', 'B-VP', 'O')
('Taq', 'Taq', 'NN', 'B-NP', 'B-protein')
('polymerase', 'polymerase', 'NN', 'I-NP', 'O')
('(Promega)', '(Promega)', 'NN', 'I-NP', 'O')
('according', 'accord', 'VBG', 'B-PP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('manufacturer’s', 'manufacturer’', 'NNS', 'I-NP', 'O')
('instructions.', 'instructions.', 'NNS', 'I-NP', 'O')
For restriction fragment length polymorphism (RFLP) analysis of MTHFR -C677T, TGFA -C3296T, and IRF6 -G820A, the PCR-amplicons were digested with Hinf I, Dra I, or Dpn II, respectively.
('For', 'For', 'IN', 'B-PP', 'O')
('restriction', 'restriction', 'NN', 'B-NP', 'O')
('fragment', 'fragment', 'NN', 'I-NP', 'O')
('length', 'length', 'NN', 'I-NP', 'O')
('polymorphism', 'polymorphism', 'NN', 'I-NP', 'O')
('(RFLP)', '(RFLP)', 'NN', 'I-NP', 'O')
('analysis', 'analysis', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('MTHFR', 'MTHFR', 'NN', 'B-NP', 'B-protein')
('-C677T,', '-C677T,', 'NN', 'I-NP', 'O')
('TGFA', 'TGFA', 'NN', 'I-NP', 'O')
('-C3296T,', '-C3296T,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('IRF6', 'IRF6', 'NN', 'I-NP', 'B-protein')
('-G820A,', '-G820A,', 'NN', 'I-NP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('PCR-amplicons', 'PCR-amplicon', 'NNS', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('digested', 'digest', 'VBN', 'I-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('Hinf', 'Hinf', 'NNP', 'B-NP', 'O')
('I,', 'I,', 'NNP', 'I-NP', 'O')
('Dra', 'Dra', 'NNP', 'I-NP', 'O')
('I,', 'I,', 'NNP', 'I-NP', 'O')
('or', 'or', 'CC', 'O', 'O')
('Dpn', 'Dpn', 'NNP', 'B-NP', 'O')
('II,', 'II,', 'NNP', 'I-NP', 'O')
('respectively.', 'respectively.', 'NN', 'I-NP', 'O')
After digestion with the appropriate restriction enzyme, the DNA fragments were analyzed by electrophoresis in 10% non-denaturing polyacrylamide gels or 2.5% agarose gels.
('After', 'After', 'IN', 'B-PP', 'O')
('digestion', 'digestion', 'NN', 'B-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('appropriate', 'appropriate', 'JJ', 'I-NP', 'O')
('restriction', 'restriction', 'NN', 'I-NP', 'O')
('enzyme,', 'enzyme,', 'VBD', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('DNA', 'DNA', 'NN', 'I-NP', 'B-DNA')
('fragments', 'fragment', 'NNS', 'I-NP', 'I-DNA')
('were', 'be', 'VBD', 'B-VP', 'O')
('analyzed', 'analyze', 'VBN', 'I-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('electrophoresis', 'electrophoresis', 'NN', 'B-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('10%', '10%', 'CD', 'B-NP', 'O')
('non-denaturing', 'non-denaturing', 'JJ', 'I-NP', 'O')
('polyacrylamide', 'polyacrylamide', 'NN', 'I-NP', 'O')
('gels', 'gel', 'NNS', 'I-NP', 'O')
('or', 'or', 'CC', 'O', 'O')
('2.5%', '2.5%', 'CD', 'B-NP', 'O')
('agarose', 'agarose', 'NN', 'I-NP', 'O')
('gels.', 'gels.', 'NNS', 'I-NP', 'O')
For the analysis of TGFA -T3827C which does not have an informative restriction site, genotyping was performed by sequencing the PCR-amplified fragments using the Cycle Sequencing Ready Reaction Kit (Applied Biosystems).
('For', 'For', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('analysis', 'analysis', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('TGFA', 'TGFA', 'NN', 'B-NP', 'B-protein')
('-T3827C', '-T3827C', 'NN', 'I-NP', 'I-protein')
('which', 'which', 'WDT', 'B-NP', 'O')
('does', 'do', 'VBZ', 'B-VP', 'O')
('not', 'not', 'RB', 'I-VP', 'O')
('have', 'have', 'VB', 'I-VP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('informative', 'informative', 'JJ', 'I-NP', 'O')
('restriction', 'restriction', 'NN', 'I-NP', 'O')
('site,', 'site,', 'NN', 'I-NP', 'O')
('genotyping', 'genotyping', 'NN', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('performed', 'perform', 'VBN', 'I-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('sequencing', 'sequence', 'VBG', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('PCR-amplified', 'PCR-amplified', 'JJ', 'I-NP', 'B-DNA')
('fragments', 'fragment', 'NNS', 'I-NP', 'I-DNA')
('using', 'use', 'VBG', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('Cycle', 'Cycle', 'NNP', 'I-NP', 'O')
('Sequencing', 'Sequencing', 'NNP', 'I-NP', 'O')
('Ready', 'Ready', 'NNP', 'I-NP', 'O')
('Reaction', 'Reaction', 'NNP', 'I-NP', 'O')
('Kit', 'Kit', 'NNP', 'I-NP', 'O')
('(Applied', '(Applied', 'NNP', 'I-NP', 'O')
('Biosystems).', 'Biosystems).', 'NNP', 'I-NP', 'O')
Sequence scanning was carried out using an ABI 3100 genetic analyzer (Applied Biosystems).
('Sequence', 'Sequence', 'NN', 'B-NP', 'O')
('scanning', 'scanning', 'NN', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('carried', 'carry', 'VBN', 'I-VP', 'O')
('out', 'out', 'RP', 'B-PRT', 'O')
('using', 'use', 'VBG', 'B-VP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('ABI', 'ABI', 'NNP', 'I-NP', 'O')
('3100', '3100', 'CD', 'I-NP', 'O')
('genetic', 'genetic', 'JJ', 'I-NP', 'O')
('analyzer', 'analyzer', 'NN', 'I-NP', 'O')
('(Applied', '(Applied', 'NNP', 'I-NP', 'O')
('Biosystems).', 'Biosystems).', 'NNP', 'I-NP', 'O')
Allele frequencies in CL/P patients and controls were determined by counting alleles and calculating sample proportions.
('Allele', 'Allele', 'NN', 'B-NP', 'O')
('frequencies', 'frequency', 'NNS', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('CL/P', 'CL/P', 'NN', 'B-NP', 'O')
('patients', 'patient', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('controls', 'control', 'NNS', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('determined', 'determine', 'VBN', 'I-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('counting', 'count', 'VBG', 'B-VP', 'O')
('alleles', 'allele', 'NNS', 'B-NP', 'B-DNA')
('and', 'and', 'CC', 'O', 'O')
('calculating', 'calculate', 'VBG', 'B-VP', 'O')
('sample', 'sample', 'NN', 'B-NP', 'O')
('proportions.', 'proportions.', 'NNS', 'I-NP', 'O')
The Hardy-Weinberg equilibrium was evaluated for all markers.
('The', 'The', 'DT', 'B-NP', 'O')
('Hardy-Weinberg', 'Hardy-Weinberg', 'NNP', 'I-NP', 'O')
('equilibrium', 'equilibrium', 'NN', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('evaluated', 'evaluate', 'VBN', 'I-VP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('all', 'all', 'DT', 'B-NP', 'O')
('markers.', 'markers.', 'NNS', 'I-NP', 'O')
Fisher’s exact2P -values less than 0.05 were considered to indicate statistical significance.
('Fisher’s', 'Fisher’', 'NNS', 'B-NP', 'O')
('exact', 'exact', 'VBP', 'B-VP', 'O')
('2', '2', 'CD', 'B-NP', 'O')
('P', 'P', 'NN', 'I-NP', 'O')
('-values', '-value', 'NNS', 'I-NP', 'O')
('less', 'less', 'JJR', 'B-NP', 'O')
('than', 'than', 'IN', 'I-NP', 'O')
('0.05', '0.05', 'CD', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('considered', 'consider', 'VBN', 'I-VP', 'O')
('to', 'to', 'TO', 'I-VP', 'O')
('indicate', 'indicate', 'VB', 'I-VP', 'O')
('statistical', 'statistical', 'JJ', 'B-NP', 'O')
('significance.', 'significance.', 'NN', 'I-NP', 'O')
The genotypes at MTHFR -C677T, TGFA -C3296T, andIRF6 -G820A were determined by RFLP analysis.
('The', 'The', 'DT', 'B-NP', 'O')
('genotypes', 'genotype', 'NNS', 'I-NP', 'O')
('at', 'at', 'IN', 'B-PP', 'O')
('MTHFR', 'MTHFR', 'NN', 'B-NP', 'B-protein')
('-C677T,', '-C677T,', 'NN', 'I-NP', 'O')
('TGFA', 'TGFA', 'NN', 'I-NP', 'O')
('-C3296T,', '-C3296T,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('IRF6', 'IRF6', 'NN', 'B-NP', 'B-protein')
('-G820A', '-G820A', 'NN', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('determined', 'determine', 'VBN', 'I-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('RFLP', 'RFLP', 'NN', 'B-NP', 'B-protein')
('analysis.', 'analysis.', 'NNS', 'I-NP', 'I-protein')
A nucleotide change from C to T at position 667 of MTHFR creates a Hinf I restriction site resulting in fragments of 175 bp and 71 bp following Hinf I digestion of the 246 bp DNA.
('A', 'A', 'DT', 'B-NP', 'O')
('nucleotide', 'nucleotide', 'NN', 'I-NP', 'O')
('change', 'change', 'NN', 'I-NP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('C', 'C', 'NN', 'B-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('T', 'T', 'NN', 'B-NP', 'O')
('at', 'at', 'IN', 'B-PP', 'O')
('position', 'position', 'NN', 'B-NP', 'B-protein')
('667', '667', 'CD', 'I-NP', 'I-protein')
('of', 'of', 'IN', 'B-PP', 'O')
('MTHFR', 'MTHFR', 'NN', 'B-NP', 'B-protein')
('creates', 'create', 'VBZ', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('Hinf', 'Hinf', 'NN', 'I-NP', 'B-DNA')
('I', 'I', 'CD', 'I-NP', 'I-DNA')
('restriction', 'restriction', 'NN', 'I-NP', 'I-DNA')
('site', 'site', 'NN', 'I-NP', 'I-DNA')
('resulting', 'result', 'VBG', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('fragments', 'fragment', 'NNS', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('175', '175', 'CD', 'B-NP', 'O')
('bp', 'bp', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('71', '71', 'CD', 'B-NP', 'O')
('bp', 'bp', 'NN', 'I-NP', 'O')
('following', 'follow', 'VBG', 'B-PP', 'O')
('Hinf', 'Hinf', 'NN', 'B-NP', 'O')
('I', 'I', 'CD', 'I-NP', 'O')
('digestion', 'digestion', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('246', '246', 'CD', 'I-NP', 'O')
('bp', 'bp', 'NN', 'I-NP', 'O')
('DNA.', 'DNA.', 'NN', 'I-NP', 'O')
The 246 bp fragment represents the C allele while the 175 bp fragment represents the T allele (Fig.
('The', 'The', 'DT', 'B-NP', 'O')
('246', '246', 'CD', 'I-NP', 'B-DNA')
('bp', 'bp', 'NN', 'I-NP', 'I-DNA')
('fragment', 'fragment', 'NN', 'I-NP', 'I-DNA')
('represents', 'represent', 'VBZ', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('C', 'C', 'NN', 'I-NP', 'B-DNA')
('allele', 'allele', 'NN', 'I-NP', 'I-DNA')
('while', 'while', 'IN', 'B-SBAR', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('175', '175', 'CD', 'I-NP', 'B-DNA')
('bp', 'bp', 'NN', 'I-NP', 'I-DNA')
('fragment', 'fragment', 'NN', 'I-NP', 'I-DNA')
('represents', 'represent', 'VBZ', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('T', 'T', 'NN', 'I-NP', 'O')
('allele', 'allele', 'NN', 'I-NP', 'O')
('(Fig.', '(Fig.', 'NN', 'I-NP', 'O')
1A).
('1A).', '1A).', 'NN', 'B-NP', 'O')
Similarly, aC to T change at TGF α -C3296T creates a Dra I restrictionsite that leads to digestion of the 98 bp fragments into 70 bp and 28 bp fragments (Fig.
('Similarly,', 'Similarly,', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('C', 'C', 'NN', 'I-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('T', 'T', 'NN', 'B-NP', 'O')
('change', 'change', 'NN', 'I-NP', 'O')
('at', 'at', 'IN', 'B-PP', 'O')
('TGF', 'TGF', 'NN', 'B-NP', 'B-protein')
('α', 'α', 'NN', 'I-NP', 'O')
('-C3296T', '-C3296T', 'NN', 'I-NP', 'O')
('creates', 'create', 'VBZ', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('Dra', 'Dra', 'NN', 'I-NP', 'B-DNA')
('I', 'I', 'CD', 'I-NP', 'I-DNA')
('restriction', 'restriction', 'NN', 'I-NP', 'I-DNA')
('site', 'site', 'NN', 'I-NP', 'I-DNA')
('that', 'that', 'WDT', 'B-NP', 'O')
('leads', 'lead', 'VBZ', 'B-VP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('digestion', 'digestion', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('98', '98', 'CD', 'I-NP', 'B-DNA')
('bp', 'bp', 'NN', 'I-NP', 'I-DNA')
('fragments', 'fragment', 'NNS', 'I-NP', 'I-DNA')
('into', 'into', 'IN', 'B-PP', 'O')
('70', '70', 'CD', 'B-NP', 'B-DNA')
('bp', 'bp', 'NN', 'I-NP', 'I-DNA')
('and', 'and', 'CC', 'I-NP', 'I-DNA')
('28', '28', 'CD', 'I-NP', 'I-DNA')
('bp', 'bp', 'NN', 'I-NP', 'I-DNA')
('fragments', 'fragment', 'NNS', 'I-NP', 'I-DNA')
('(Fig.', '(Fig.', 'NNP', 'B-NP', 'O')
1B).
('1B).', '1B).', 'LS', 'B-LST', 'O')
In the case of IRF6 -G820A, a G to A change introduces a Dpn II restriction site leading to digestion of the 298 bp fragments into 234 bp and 64 bp fragments (Fig.
('In', 'In', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('case', 'case', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('IRF6', 'IRF6', 'NN', 'B-NP', 'B-protein')
('-G820A,', '-G820A,', 'NN', 'I-NP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('G', 'G', 'NN', 'I-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('A', 'A', 'NN', 'B-NP', 'O')
('change', 'change', 'NN', 'I-NP', 'O')
('introduces', 'introduce', 'VBZ', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('Dpn', 'Dpn', 'NN', 'I-NP', 'B-DNA')
('II', 'II', 'CD', 'I-NP', 'I-DNA')
('restriction', 'restriction', 'NN', 'I-NP', 'I-DNA')
('site', 'site', 'NN', 'I-NP', 'I-DNA')
('leading', 'lead', 'VBG', 'B-VP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('digestion', 'digestion', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('298', '298', 'CD', 'I-NP', 'B-DNA')
('bp', 'bp', 'NN', 'I-NP', 'I-DNA')
('fragments', 'fragment', 'NNS', 'I-NP', 'I-DNA')
('into', 'into', 'IN', 'B-PP', 'O')
('234', '234', 'CD', 'B-NP', 'O')
('bp', 'bp', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('64', '64', 'CD', 'B-NP', 'B-DNA')
('bp', 'bp', 'NN', 'I-NP', 'I-DNA')
('fragments', 'fragment', 'NNS', 'I-NP', 'I-DNA')
('(Fig.', '(Fig.', 'NNP', 'B-NP', 'O')
1C).
('1C).', '1C).', 'LS', 'B-LST', 'O')
Genotypes at TGFA -T3827C were assessed by DNA sequencing analysis of the PCR-amplified fragments.
('Genotypes', 'Genotype', 'NNS', 'B-NP', 'O')
('at', 'at', 'IN', 'B-PP', 'O')
('TGFA', 'TGFA', 'NN', 'B-NP', 'O')
('-T3827C', '-T3827C', 'NN', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('assessed', 'assess', 'VBN', 'I-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('DNA', 'DNA', 'NN', 'B-NP', 'O')
('sequencing', 'sequencing', 'NN', 'I-NP', 'O')
('analysis', 'analysis', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('PCR-amplified', 'PCR-amplified', 'JJ', 'I-NP', 'O')
('fragments.', 'fragments.', 'NN', 'I-NP', 'O')
Genotype frequencies of MTHFR -C677T, TGFA -C3296T, TGFA -T3827C, and IRF6 -G820A in CL/P patients and normal controls are summarized in Table 2.
('Genotype', 'Genotype', 'NN', 'B-NP', 'O')
('frequencies', 'frequency', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('MTHFR', 'MTHFR', 'NN', 'B-NP', 'B-protein')
('-C677T,', '-C677T,', 'NN', 'I-NP', 'O')
('TGFA', 'TGFA', 'NN', 'I-NP', 'O')
('-C3296T,', '-C3296T,', 'NN', 'I-NP', 'O')
('TGFA', 'TGFA', 'NN', 'I-NP', 'O')
('-T3827C,', '-T3827C,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('IRF6', 'IRF6', 'NN', 'B-NP', 'B-protein')
('-G820A', '-G820A', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('CL/P', 'CL/P', 'NN', 'B-NP', 'O')
('patients', 'patient', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('normal', 'normal', 'JJ', 'B-NP', 'O')
('controls', 'control', 'NNS', 'I-NP', 'O')
('are', 'be', 'VBP', 'B-VP', 'O')
('summarized', 'summarize', 'VBN', 'I-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('Table', 'Table', 'JJ', 'B-NP', 'O')
('2.', '2.', 'CD', 'I-NP', 'O')
At MTHFR -C677T, TGFA -C3296T, and IRF6 -G820A, there were no statistically significant differences in the genotype frequencies between CL/P patients and controls.
('At', 'At', 'IN', 'B-PP', 'O')
('MTHFR', 'MTHFR', 'NN', 'B-NP', 'B-protein')
('-C677T,', '-C677T,', 'NN', 'I-NP', 'O')
('TGFA', 'TGFA', 'NN', 'I-NP', 'O')
('-C3296T,', '-C3296T,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('IRF6', 'IRF6', 'NN', 'B-NP', 'B-protein')
('-G820A,', '-G820A,', 'NN', 'I-NP', 'O')
('there', 'there', 'EX', 'B-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('no', 'no', 'DT', 'B-NP', 'O')
('statistically', 'statistically', 'RB', 'I-NP', 'O')
('significant', 'significant', 'JJ', 'I-NP', 'O')
('differences', 'difference', 'NNS', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('genotype', 'genotype', 'NN', 'I-NP', 'O')
('frequencies', 'frequency', 'NNS', 'I-NP', 'O')
('between', 'between', 'IN', 'B-PP', 'O')
('CL/P', 'CL/P', 'NN', 'B-NP', 'O')
('patients', 'patient', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('controls.', 'controls.', 'NNS', 'I-NP', 'O')
In contrast, the genotype frequencies of TGFA -T3827C were significantly different between the patient and control groups with a P -value of 0.004 (Table.
('In', 'In', 'IN', 'B-PP', 'O')
('contrast,', 'contrast,', 'NN', 'B-NP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('genotype', 'genotype', 'NN', 'I-NP', 'O')
('frequencies', 'frequency', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('TGFA', 'TGFA', 'NN', 'B-NP', 'O')
('-T3827C', '-T3827C', 'NN', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('significantly', 'significantly', 'RB', 'B-ADJP', 'O')
('different', 'different', 'JJ', 'I-ADJP', 'O')
('between', 'between', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('patient', 'patient', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('control', 'control', 'NN', 'I-NP', 'O')
('groups', 'group', 'NNS', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('P', 'P', 'NN', 'I-NP', 'O')
('-value', '-value', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('0.004', '0.004', 'CD', 'B-NP', 'O')
('(Table.', '(Table.', 'NNP', 'B-NP', 'O')
2), indicating that the TT polymorphism is significantly associated with CL/P in the patient group tested.
('2),', '2),', 'LS', 'B-LST', 'O')
('indicating', 'indicate', 'VBG', 'B-VP', 'O')
('that', 'that', 'IN', 'B-SBAR', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('TT', 'TT', 'NN', 'I-NP', 'B-DNA')
('polymorphism', 'polymorphism', 'NN', 'I-NP', 'I-DNA')
('is', 'be', 'VBZ', 'B-VP', 'O')
('significantly', 'significantly', 'RB', 'I-VP', 'O')
('associated', 'associate', 'VBN', 'I-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('CL/P', 'CL/P', 'NN', 'B-NP', 'B-protein')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('patient', 'patient', 'NN', 'I-NP', 'O')
('group', 'group', 'NN', 'I-NP', 'O')
('tested.', 'tested.', 'NN', 'I-NP', 'O')
However, there was no statistically significantMTHFR plays a key role in the metabolism of folate.
('However,', 'However,', 'WRB', 'B-ADVP', 'O')
('there', 'there', 'EX', 'B-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('no', 'no', 'DT', 'B-NP', 'O')
('statistically', 'statistically', 'RB', 'I-NP', 'O')
('significant', 'significant', 'JJ', 'I-NP', 'O')
('MTHFR', 'MTHFR', 'NN', 'I-NP', 'B-protein')
('plays', 'play', 'VBZ', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('key', 'key', 'JJ', 'I-NP', 'O')
('role', 'role', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('metabolism', 'metabolism', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('folate.', 'folate.', 'NN', 'B-NP', 'O')
The C677T change in MTHFR leads to the substitution of a highly conserved alanine residue into a valine residue in the catalytic domain of MTHFR.
('The', 'The', 'DT', 'B-NP', 'O')
('C677T', 'C677T', 'NN', 'I-NP', 'O')
('change', 'change', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('MTHFR', 'MTHFR', 'NN', 'B-NP', 'B-protein')
('leads', 'lead', 'VBZ', 'B-VP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('substitution', 'substitution', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('highly', 'highly', 'RB', 'I-NP', 'O')
('conserved', 'conserve', 'VBN', 'I-NP', 'O')
('alanine', 'alanine', 'NN', 'I-NP', 'O')
('residue', 'residue', 'NN', 'I-NP', 'O')
('into', 'into', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('valine', 'valine', 'NN', 'I-NP', 'O')
('residue', 'residue', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('catalytic', 'catalytic', 'JJ', 'I-NP', 'B-protein')
('domain', 'domain', 'NN', 'I-NP', 'I-protein')
('of', 'of', 'IN', 'B-PP', 'O')
('MTHFR.', 'MTHFR.', 'NN', 'B-NP', 'B-protein')
The reduced MTHFR activity resulting from the C677T mutation leads to an increase in the plasma homocysteine level and a decrease in the plasma folate level (Blom, 1998).
('The', 'The', 'DT', 'B-NP', 'O')
('reduced', 'reduce', 'VBN', 'I-NP', 'O')
('MTHFR', 'MTHFR', 'NN', 'I-NP', 'B-protein')
('activity', 'activity', 'NN', 'I-NP', 'O')
('resulting', 'result', 'VBG', 'B-VP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('C677T', 'C677T', 'NN', 'I-NP', 'O')
('mutation', 'mutation', 'NN', 'I-NP', 'O')
('leads', 'lead', 'VBZ', 'B-VP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('increase', 'increase', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('plasma', 'plasma', 'NN', 'I-NP', 'O')
('homocysteine', 'homocysteine', 'NN', 'I-NP', 'O')
('level', 'level', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('decrease', 'decrease', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('plasma', 'plasma', 'NN', 'I-NP', 'O')
('folate', 'folate', 'NN', 'I-NP', 'O')
('level', 'level', 'NN', 'I-NP', 'O')
('(Blom,', '(Blom,', 'NNP', 'B-NP', 'O')
('1998).', '1998).', 'CD', 'I-NP', 'O')
Given that the intake of folate reduces the probability of women giving birth to a child affected by a neural tube defect (NTD), this enzyme was suggested as an attractive candidate for the etiologyof CL/P (MRC Vitamin Study Research Group, 1991).
('Given', 'Give', 'VBN', 'B-VP', 'O')
('that', 'that', 'IN', 'B-SBAR', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('intake', 'intake', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('folate', 'folate', 'NN', 'B-NP', 'O')
('reduces', 'reduce', 'VBZ', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('probability', 'probability', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('women', 'woman', 'NNS', 'B-NP', 'O')
('giving', 'give', 'VBG', 'B-VP', 'O')
('birth', 'birth', 'NN', 'B-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('child', 'child', 'NN', 'I-NP', 'O')
('affected', 'affect', 'VBN', 'B-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('neural', 'neural', 'JJ', 'I-NP', 'B-protein')
('tube', 'tube', 'NN', 'I-NP', 'I-protein')
('defect', 'defect', 'NN', 'I-NP', 'I-protein')
('(NTD),', '(NTD),', 'NN', 'I-NP', 'I-protein')
('this', 'this', 'DT', 'B-NP', 'I-protein')
('enzyme', 'enzyme', 'NN', 'I-NP', 'I-protein')
('was', 'be', 'VBD', 'B-VP', 'O')
('suggested', 'suggest', 'VBN', 'I-VP', 'O')
('as', 'as', 'IN', 'B-PP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('attractive', 'attractive', 'JJ', 'I-NP', 'O')
('candidate', 'candidate', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('etiology', 'etiology', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('CL/P', 'CL/P', 'NNP', 'B-NP', 'O')
('(MRC', '(MRC', 'NNP', 'I-NP', 'O')
('Vitamin', 'Vitamin', 'NNP', 'I-NP', 'O')
('Study', 'Study', 'NNP', 'I-NP', 'O')
('Research', 'Research', 'NNP', 'I-NP', 'O')
('Group,', 'Group,', 'NNP', 'I-NP', 'O')
('1991).', '1991).', 'CD', 'I-NP', 'O')
Genotype analysis of several different ethnic groups has revealed higher frequencies of 677TT homozygosity in NTD patients than in controls (de Franchis et al .
('Genotype', 'Genotype', 'NN', 'B-NP', 'O')
('analysis', 'analysis', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('several', 'several', 'JJ', 'B-NP', 'O')
('different', 'different', 'JJ', 'I-NP', 'O')
('ethnic', 'ethnic', 'JJ', 'I-NP', 'O')
('groups', 'group', 'NNS', 'I-NP', 'O')
('has', 'have', 'VBZ', 'B-VP', 'O')
('revealed', 'reveal', 'VBN', 'I-VP', 'O')
('higher', 'high', 'JJR', 'B-NP', 'O')
('frequencies', 'frequency', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('677TT', '677TT', 'NN', 'B-NP', 'O')
('homozygosity', 'homozygosity', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('NTD', 'NTD', 'NN', 'B-NP', 'O')
('patients', 'patient', 'NNS', 'I-NP', 'O')
('than', 'than', 'IN', 'B-PP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('controls', 'control', 'NNS', 'B-NP', 'O')
('(de', '(de', 'VBP', 'B-VP', 'O')
('Franchis', 'Franchis', 'NNP', 'B-NP', 'O')
('et', 'et', 'FW', 'I-NP', 'O')
('al', 'al', 'FW', 'I-NP', 'O')
('.', '.', '.', 'O', 'O')
1995; Kirke et al ., 1996; Mills et al ., 1995).
('1995;', '1995;', 'CD', 'B-NP', 'O')
('Kirke', 'Kirke', 'NNP', 'I-NP', 'O')
('et', 'et', 'FW', 'I-NP', 'O')
('al', 'al', 'FW', 'I-NP', 'O')
('.,', '.,', 'VBD', 'B-VP', 'O')
('1996;', '1996;', 'CD', 'B-NP', 'O')
('Mills', 'Mills', 'NNP', 'I-NP', 'O')
('et', 'et', 'FW', 'I-NP', 'O')
('al', 'al', 'FW', 'I-NP', 'O')
('.,', '.,', 'VBD', 'B-VP', 'O')
('1995).', '1995).', 'CD', 'B-NP', 'O')
However, some studies have not shown a significant association between the C667T allele and NTD in different ethnicities (Koch et al ., 1998; Mornet et al ., 1997; Papapetrou et al ., 1996).
('However,', 'However,', 'WRB', 'B-ADVP', 'O')
('some', 'some', 'DT', 'B-NP', 'O')
('studies', 'study', 'NNS', 'I-NP', 'O')
('have', 'have', 'VBP', 'B-VP', 'O')
('not', 'not', 'RB', 'I-VP', 'O')
('shown', 'show', 'VBN', 'I-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('significant', 'significant', 'JJ', 'I-NP', 'O')
('association', 'association', 'NN', 'I-NP', 'O')
('between', 'between', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('C667T', 'C667T', 'NN', 'I-NP', 'B-DNA')
('allele', 'allele', 'NN', 'I-NP', 'I-DNA')
('and', 'and', 'CC', 'I-NP', 'O')
('NTD', 'NTD', 'NN', 'I-NP', 'B-protein')
('in', 'in', 'IN', 'B-PP', 'O')
('different', 'different', 'JJ', 'B-NP', 'O')
('ethnicities', 'ethnicity', 'NNS', 'I-NP', 'O')
('(Koch', '(Koch', 'NNP', 'B-NP', 'O')
('et', 'et', 'FW', 'I-NP', 'O')
('al', 'al', 'FW', 'I-NP', 'O')
('.,', '.,', 'FW', 'I-NP', 'O')
('1998;', '1998;', 'FW', 'I-NP', 'O')
('Mornet', 'Mornet', 'NNP', 'I-NP', 'O')
('et', 'et', 'FW', 'I-NP', 'O')
('al', 'al', 'FW', 'I-NP', 'O')
('.,', '.,', 'VBD', 'B-VP', 'O')
('1997;', '1997;', 'CD', 'B-NP', 'O')
('Papapetrou', 'Papapetrou', 'NNP', 'I-NP', 'O')
('et', 'et', 'FW', 'I-NP', 'O')
('al', 'al', 'FW', 'I-NP', 'O')
('.,', '.,', 'VBD', 'B-VP', 'O')
('1996).', '1996).', 'CD', 'B-NP', 'O')
In concurrence with previous studies, the study presented here did not show a statistically significant association between MTHFR - C677T and CL/P.
('In', 'In', 'IN', 'B-PP', 'O')
('concurrence', 'concurrence', 'NN', 'B-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('previous', 'previous', 'JJ', 'B-NP', 'O')
('studies,', 'studies,', 'NN', 'I-NP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('study', 'study', 'NN', 'I-NP', 'O')
('presented', 'present', 'VBN', 'B-VP', 'O')
('here', 'here', 'RB', 'B-ADVP', 'O')
('did', 'do', 'VBD', 'B-VP', 'O')
('not', 'not', 'RB', 'I-VP', 'O')
('show', 'show', 'VB', 'I-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('statistically', 'statistically', 'RB', 'I-NP', 'O')
('significant', 'significant', 'JJ', 'I-NP', 'O')
('association', 'association', 'NN', 'I-NP', 'O')
('between', 'between', 'IN', 'B-PP', 'O')
('MTHFR', 'MTHFR', 'NN', 'B-NP', 'B-protein')
('-', '-', 'HYPH', 'I-NP', 'O')
('C677T', 'C677T', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('CL/P.', 'CL/P.', 'NN', 'I-NP', 'O')
We detected approximately similar frequencies of 677TT homozygosity in both CL/P and control groups.
('We', 'We', 'PRP', 'B-NP', 'O')
('detected', 'detect', 'VBD', 'B-VP', 'O')
('approximately', 'approximately', 'RB', 'B-NP', 'O')
('similar', 'similar', 'JJ', 'I-NP', 'O')
('frequencies', 'frequency', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('677TT', '677TT', 'NN', 'B-NP', 'O')
('homozygosity', 'homozygosity', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('both', 'both', 'CC', 'O', 'O')
('CL/P', 'CL/P', 'NN', 'B-NP', 'B-protein')
('and', 'and', 'CC', 'I-NP', 'O')
('control', 'control', 'NN', 'I-NP', 'O')
('groups.', 'groups.', 'NNS', 'I-NP', 'O')
Van der Woude syndrome (VWS; OMIM 119300) is an autosomal dominant disorder characterized by congenital lip pits with CL/P.
('Van', 'Van', 'NNP', 'B-NP', 'O')
('der', 'der', 'NNP', 'I-NP', 'O')
('Woude', 'Woude', 'NNP', 'I-NP', 'O')
('syndrome', 'syndrome', 'NN', 'I-NP', 'O')
('(VWS;', '(VWS;', 'NN', 'I-NP', 'O')
('OMIM', 'OMIM', 'NN', 'I-NP', 'O')
('119300)', '119300)', 'NN', 'I-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('autosomal', 'autosomal', 'JJ', 'I-NP', 'O')
('dominant', 'dominant', 'JJ', 'I-NP', 'O')
('disorder', 'disorder', 'NN', 'I-NP', 'O')
('characterized', 'characterize', 'VBN', 'B-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('congenital', 'congenital', 'JJ', 'B-NP', 'O')
('lip', 'lip', 'NN', 'I-NP', 'O')
('pits', 'pit', 'NNS', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('CL/P.', 'CL/P.', 'NN', 'B-NP', 'O')
VWS is the most common form of syndromic cleft lip and palate, accounting for approximately 2 % of all cleft lip and palate cases.
('VWS', 'VWS', 'NN', 'B-NP', 'B-protein')
('is', 'be', 'VBZ', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('most', 'most', 'RBS', 'I-NP', 'O')
('common', 'common', 'JJ', 'I-NP', 'O')
('form', 'form', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('syndromic', 'syndromic', 'JJ', 'B-NP', 'O')
('cleft', 'cleft', 'NN', 'I-NP', 'O')
('lip', 'lip', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('palate,', 'palate,', 'NN', 'B-NP', 'O')
('accounting', 'accounting', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('approximately', 'approximately', 'RB', 'B-NP', 'O')
('2', '2', 'CD', 'I-NP', 'O')
('%', '%', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('all', 'all', 'DT', 'B-NP', 'O')
('cleft', 'cleft', 'JJ', 'I-NP', 'O')
('lip', 'lip', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('palate', 'palate', 'NN', 'I-NP', 'O')
('cases.', 'cases.', 'NNS', 'I-NP', 'O')
It is distinguished from nonsyndromic cleft lip and palate by the presence of lower lip pits (Burdick et al ., 1985).
('It', 'It', 'PRP', 'B-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('distinguished', 'distinguish', 'VBN', 'I-VP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('nonsyndromic', 'nonsyndromic', 'JJ', 'B-NP', 'O')
('cleft', 'cleft', 'NN', 'I-NP', 'O')
('lip', 'lip', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('palate', 'palate', 'NN', 'I-NP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('presence', 'presence', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('lower', 'low', 'JJR', 'B-NP', 'O')
('lip', 'lip', 'NN', 'I-NP', 'O')
('pits', 'pit', 'NNS', 'I-NP', 'O')
('(Burdick', '(Burdick', 'NNP', 'I-NP', 'O')
('et', 'et', 'FW', 'I-NP', 'O')
('al', 'al', 'FW', 'I-NP', 'O')
('.,', '.,', 'IN', 'B-PP', 'O')
('1985).', '1985).', 'CD', 'B-NP', 'O')
By direct sequence analysis of the genomic VWS region of a pair of monozygotic twins discordant for the VWS phenotype, IRF6 was identified as the gene mutated in this orofacial malformation, suggesting a possibility that IRF6 may also play a role in nonsyndromic CL/P (Kondo et al ., 2002).
('By', 'By', 'IN', 'B-PP', 'O')
('direct', 'direct', 'JJ', 'B-NP', 'O')
('sequence', 'sequence', 'NN', 'I-NP', 'O')
('analysis', 'analysis', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('genomic', 'genomic', 'JJ', 'I-NP', 'B-DNA')
('VWS', 'VWS', 'NN', 'I-NP', 'I-DNA')
('region', 'region', 'NN', 'I-NP', 'I-DNA')
('of', 'of', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('pair', 'pair', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('monozygotic', 'monozygotic', 'JJ', 'B-NP', 'O')
('twins', 'twin', 'NNS', 'I-NP', 'O')
('discordant', 'discordant', 'JJ', 'B-ADJP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('VWS', 'VWS', 'NN', 'I-NP', 'B-protein')
('phenotype,', 'phenotype,', 'NN', 'I-NP', 'I-protein')
('IRF6', 'IRF6', 'NN', 'I-NP', 'I-protein')
('was', 'be', 'VBD', 'B-VP', 'O')
('identified', 'identify', 'VBN', 'I-VP', 'O')
('as', 'as', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('gene', 'gene', 'NN', 'I-NP', 'O')
('mutated', 'mutate', 'VBN', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('this', 'this', 'DT', 'B-NP', 'O')
('orofacial', 'orofacial', 'JJ', 'I-NP', 'O')
('malformation,', 'malformation,', 'NN', 'I-NP', 'O')
('suggesting', 'suggest', 'VBG', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('possibility', 'possibility', 'NN', 'I-NP', 'O')
('that', 'that', 'IN', 'B-SBAR', 'O')
('IRF6', 'IRF6', 'NN', 'B-NP', 'B-protein')
('may', 'may', 'MD', 'B-VP', 'O')
('also', 'also', 'RB', 'I-VP', 'O')
('play', 'play', 'VB', 'I-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('role', 'role', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('nonsyndromic', 'nonsyndromic', 'JJ', 'B-NP', 'O')
('CL/P', 'CL/P', 'NN', 'I-NP', 'O')
('(Kondo', '(Kondo', 'NNP', 'I-NP', 'O')
('et', 'et', 'FW', 'I-NP', 'O')
('al', 'al', 'FW', 'I-NP', 'O')
('.,', '.,', 'NN', 'I-NP', 'O')
('2002).', '2002).', '.', 'O', 'O')
Recently, several studies have reported that a single nucleotide polymorphism, G820A in IRF6 , is associated with CL/P in several different ethnic groups (Scapoli et al ., 2005; Zucchero et al ., 2004).
('Recently,', 'Recently,', 'IN', 'B-PP', 'O')
('several', 'several', 'JJ', 'B-NP', 'O')
('studies', 'study', 'NNS', 'I-NP', 'O')
('have', 'have', 'VBP', 'B-VP', 'O')
('reported', 'report', 'VBN', 'I-VP', 'O')
('that', 'that', 'IN', 'B-SBAR', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('single', 'single', 'JJ', 'I-NP', 'O')
('nucleotide', 'nucleotide', 'NN', 'I-NP', 'O')
('polymorphism,', 'polymorphism,', 'NN', 'I-NP', 'O')
('G820A', 'G820A', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('IRF6', 'IRF6', 'NN', 'B-NP', 'B-protein')
(',', ',', ',', 'O', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('associated', 'associate', 'VBN', 'I-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('CL/P', 'CL/P', 'NN', 'B-NP', 'B-protein')
('in', 'in', 'IN', 'B-PP', 'O')
('several', 'several', 'JJ', 'B-NP', 'O')
('different', 'different', 'JJ', 'I-NP', 'O')
('ethnic', 'ethnic', 'JJ', 'I-NP', 'O')
('groups', 'group', 'NNS', 'I-NP', 'O')
('(Scapoli', '(Scapoli', 'NNP', 'B-NP', 'O')
('et', 'et', 'FW', 'I-NP', 'O')
('al', 'al', 'FW', 'I-NP', 'O')
('.,', '.,', 'FW', 'I-NP', 'O')
('2005;', '2005;', 'FW', 'I-NP', 'O')
('Zucchero', 'Zucchero', 'NNP', 'I-NP', 'O')
('et', 'et', 'FW', 'I-NP', 'O')
('al', 'al', 'FW', 'I-NP', 'O')
('.,', '.,', 'VBD', 'B-VP', 'O')
('2004).', '2004).', 'CD', 'B-NP', 'O')
The G820A polymorphism results in a substitution from valine to isoleucine at codon 274, which is located in a putative Smad-interferon regulatory factor-binding domain of IRF6.
('The', 'The', 'DT', 'B-NP', 'O')
('G820A', 'G820A', 'NN', 'I-NP', 'B-DNA')
('polymorphism', 'polymorphism', 'NN', 'I-NP', 'I-DNA')
('results', 'result', 'VBZ', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('substitution', 'substitution', 'NN', 'I-NP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('valine', 'valine', 'NN', 'B-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('isoleucine', 'isoleucine', 'NN', 'B-NP', 'O')
('at', 'at', 'IN', 'B-PP', 'O')
('codon', 'codon', 'NN', 'B-NP', 'B-DNA')
('274,', '274,', 'CD', 'I-NP', 'I-DNA')
('which', 'which', 'WDT', 'B-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('located', 'located', 'JJ', 'B-ADJP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('putative', 'putative', 'JJ', 'I-NP', 'B-protein')
('Smad-interferon', 'Smad-interferon', 'NN', 'I-NP', 'I-protein')
('regulatory', 'regulatory', 'JJ', 'I-NP', 'I-protein')
('factor-binding', 'factor-binding', 'JJ', 'I-NP', 'I-protein')
('domain', 'domain', 'NN', 'I-NP', 'I-protein')
('of', 'of', 'IN', 'B-PP', 'O')
('IRF6.', 'IRF6.', 'NN', 'B-NP', 'B-protein')
The Smad proteins are a family of transcription factors known to transduce signals from the TGF- β superfamily (Brivanlou et al ., 2002).
('The', 'The', 'DT', 'B-NP', 'O')
('Smad', 'Smad', 'NN', 'I-NP', 'B-protein')
('proteins', 'protein', 'NNS', 'I-NP', 'I-protein')
('are', 'be', 'VBP', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('family', 'family', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('transcription', 'transcription', 'NN', 'B-NP', 'B-protein')
('factors', 'factor', 'NNS', 'I-NP', 'I-protein')
('known', 'know', 'VBN', 'B-VP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('transduce', 'transduce', 'VB', 'I-VP', 'O')
('signals', 'signal', 'NNS', 'B-NP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('TGF-', 'TGF-', 'NN', 'I-NP', 'B-protein')
('β', 'β', 'NN', 'I-NP', 'I-protein')
('superfamily', 'superfamily', 'NN', 'I-NP', 'I-protein')
('(Brivanlou', '(Brivanlou', 'FW', 'B-NP', 'O')
('et', 'et', 'FW', 'I-NP', 'O')
('al', 'al', 'FW', 'I-NP', 'O')
('.,', '.,', 'VBD', 'B-VP', 'O')
('2002).', '2002).', 'CD', 'B-NP', 'O')
However, in our study the G820A was not significantly associated with nonsyndromic CL/P, but the A allele was less frequently found in CL/P than in controls.
('However,', 'However,', 'WRB', 'B-ADVP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('our', 'our', 'PRP$', 'B-NP', 'O')
('study', 'study', 'NN', 'I-NP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('G820A', 'G820A', 'NN', 'I-NP', 'B-protein')
('was', 'be', 'VBD', 'B-VP', 'O')
('not', 'not', 'RB', 'I-VP', 'O')
('significantly', 'significantly', 'RB', 'I-VP', 'O')
('associated', 'associate', 'VBN', 'I-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('nonsyndromic', 'nonsyndromic', 'JJ', 'B-NP', 'O')
('CL/P,', 'CL/P,', 'NN', 'I-NP', 'O')
('but', 'but', 'CC', 'O', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('A', 'A', 'NN', 'I-NP', 'B-DNA')
('allele', 'allele', 'NN', 'I-NP', 'I-DNA')
('was', 'be', 'VBD', 'B-VP', 'O')
('less', 'less', 'RBR', 'I-VP', 'O')
('frequently', 'frequently', 'RB', 'I-VP', 'O')
('found', 'find', 'VBN', 'I-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('CL/P', 'CL/P', 'NN', 'B-NP', 'B-protein')
('than', 'than', 'IN', 'B-PP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('controls.', 'controls.', 'NN', 'B-NP', 'O')
These contradictory results may reflect genetic heterogeneity, incomplete penetrance, or limited sample sizes.
('These', 'These', 'DT', 'B-NP', 'O')
('contradictory', 'contradictory', 'JJ', 'I-NP', 'O')
('results', 'result', 'NNS', 'I-NP', 'O')
('may', 'may', 'MD', 'B-VP', 'O')
('reflect', 'reflect', 'VB', 'I-VP', 'O')
('genetic', 'genetic', 'JJ', 'B-NP', 'O')
('heterogeneity,', 'heterogeneity,', 'NN', 'I-NP', 'O')
('incomplete', 'incomplete', 'JJ', 'I-NP', 'O')
('penetrance,', 'penetrance,', 'NN', 'I-NP', 'O')
('or', 'or', 'CC', 'O', 'O')
('limited', 'limited', 'JJ', 'B-NP', 'O')
('sample', 'sample', 'NN', 'I-NP', 'O')
('sizes.', 'sizes.', 'NN', 'I-NP', 'O')
During craniofacial development, TGF α , a well characterized mammalian growth factor, is expressed in the medial edge of the epithelium of fusing palatal shelves, and promotes synthesis of extracellular matrix and mesenchymal cell migration into the palates (Dixon et al ., 1991).
('During', 'During', 'IN', 'B-PP', 'O')
('craniofacial', 'craniofacial', 'JJ', 'B-NP', 'O')
('development,', 'development,', 'NN', 'I-NP', 'O')
('TGF', 'TGF', 'NN', 'I-NP', 'O')
('α', 'α', 'NN', 'I-NP', 'O')
(',', ',', ',', 'O', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('well', 'well', 'RB', 'I-NP', 'O')
('characterized', 'characterize', 'VBN', 'I-NP', 'O')
('mammalian', 'mammalian', 'JJ', 'I-NP', 'B-protein')
('growth', 'growth', 'NN', 'I-NP', 'I-protein')
('factor,', 'factor,', 'NN', 'I-NP', 'I-protein')
('is', 'be', 'VBZ', 'B-VP', 'O')
('expressed', 'express', 'VBN', 'I-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('medial', 'medial', 'JJ', 'I-NP', 'O')
('edge', 'edge', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('epithelium', 'epithelium', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('fusing', 'fuse', 'VBG', 'B-VP', 'O')
('palatal', 'palatal', 'JJ', 'B-NP', 'O')
('shelves,', 'shelves,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('promotes', 'promote', 'VBZ', 'B-VP', 'O')
('synthesis', 'synthesis', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('extracellular', 'extracellular', 'JJ', 'B-NP', 'O')
('matrix', 'matrix', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('mesenchymal', 'mesenchymal', 'JJ', 'B-NP', 'O')
('cell', 'cell', 'NN', 'I-NP', 'O')
('migration', 'migration', 'NN', 'I-NP', 'O')
('into', 'into', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('palates', 'palate', 'VBZ', 'B-VP', 'O')
('(Dixon', '(Dixon', 'NNP', 'B-NP', 'O')
('et', 'et', 'FW', 'I-NP', 'O')
('al', 'al', 'FW', 'I-NP', 'O')
('.,', '.,', 'VBD', 'B-VP', 'O')
('1991).', '1991).', 'CD', 'B-NP', 'O')
A number of studies have reported genotype analysis of CL/P patients with genetic markers in TGFA since the first finding that polymorphisms in TGFA were associated with nonsyndromic CL/P (Ardinger et al ., 1989).
('A', 'A', 'DT', 'B-NP', 'O')
('number', 'number', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('studies', 'study', 'NNS', 'B-NP', 'O')
('have', 'have', 'VBP', 'B-VP', 'O')
('reported', 'report', 'VBN', 'I-VP', 'O')
('genotype', 'genotype', 'NN', 'B-NP', 'O')
('analysis', 'analysis', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('CL/P', 'CL/P', 'NN', 'B-NP', 'O')
('patients', 'patient', 'NNS', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('genetic', 'genetic', 'JJ', 'B-NP', 'O')
('markers', 'marker', 'NNS', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('TGFA', 'TGFA', 'NN', 'B-NP', 'B-protein')
('since', 'since', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('first', 'first', 'JJ', 'I-NP', 'O')
('finding', 'finding', 'NN', 'I-NP', 'O')
('that', 'that', 'IN', 'B-SBAR', 'O')
('polymorphisms', 'polymorphism', 'NNS', 'B-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('TGFA', 'TGFA', 'NN', 'B-NP', 'B-protein')
('were', 'be', 'VBD', 'B-VP', 'O')
('associated', 'associate', 'VBN', 'I-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('nonsyndromic', 'nonsyndromic', 'JJ', 'B-NP', 'O')
('CL/P', 'CL/P', 'NN', 'I-NP', 'O')
('(Ardinger', '(Ardinger', 'NNP', 'I-NP', 'O')
('et', 'et', 'FW', 'I-NP', 'O')
('al', 'al', 'FW', 'I-NP', 'O')
('.,', '.,', 'IN', 'B-PP', 'O')
('1989).', '1989).', 'CD', 'B-NP', 'O')
In the genotyping studies presented here, TGFA -T3827C showed a statistically significant association with CL/P, with a higher frequency of the TT genotype in CL/P patients than in controls, while TGFA -C3296T displayed no statisticalsignificance in its association with CL/P.
('In', 'In', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('genotyping', 'genotyping', 'NN', 'I-NP', 'O')
('studies', 'study', 'NNS', 'I-NP', 'O')
('presented', 'present', 'VBD', 'B-VP', 'O')
('here,', 'here,', 'RB', 'B-NP', 'O')
('TGFA', 'TGFA', 'NN', 'I-NP', 'O')
('-T3827C', '-T3827C', 'NN', 'I-NP', 'O')
('showed', 'show', 'VBD', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('statistically', 'statistically', 'RB', 'I-NP', 'O')
('significant', 'significant', 'JJ', 'I-NP', 'O')
('association', 'association', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('CL/P,', 'CL/P,', 'NN', 'B-NP', 'B-protein')
('with', 'with', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('higher', 'high', 'JJR', 'I-NP', 'O')
('frequency', 'frequency', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('TT', 'TT', 'NN', 'I-NP', 'O')
('genotype', 'genotype', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('CL/P', 'CL/P', 'NN', 'B-NP', 'O')
('patients', 'patient', 'NNS', 'I-NP', 'O')
('than', 'than', 'IN', 'B-PP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('controls,', 'controls,', 'NN', 'B-NP', 'O')
('while', 'while', 'IN', 'B-SBAR', 'O')
('TGFA', 'TGFA', 'NN', 'B-NP', 'B-protein')
('-C3296T', '-C3296T', 'NN', 'I-NP', 'O')
('displayed', 'display', 'VBD', 'B-VP', 'O')
('no', 'no', 'DT', 'B-NP', 'O')
('statistical', 'statistical', 'JJ', 'I-NP', 'O')
('significance', 'significance', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('its', 'its', 'PRP$', 'B-NP', 'O')
('association', 'association', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('CL/P.', 'CL/P.', 'NN', 'B-NP', 'O')
Several previous studies also reported the association of TGFA -C3827T with nonsyndromic CL/P in different ethnic backgrounds including Caucasians and Filipinos (Prescott et al , 2000; Schultz et al ., 2004).
('Several', 'Several', 'JJ', 'B-NP', 'O')
('previous', 'previous', 'JJ', 'I-NP', 'O')
('studies', 'study', 'NNS', 'I-NP', 'O')
('also', 'also', 'RB', 'B-ADVP', 'O')
('reported', 'report', 'VBD', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('association', 'association', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('TGFA', 'TGFA', 'NN', 'B-NP', 'O')
('-C3827T', '-C3827T', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('nonsyndromic', 'nonsyndromic', 'JJ', 'B-NP', 'O')
('CL/P', 'CL/P', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('different', 'different', 'JJ', 'B-NP', 'O')
('ethnic', 'ethnic', 'JJ', 'I-NP', 'O')
('backgrounds', 'background', 'NNS', 'I-NP', 'O')
('including', 'include', 'VBG', 'B-PP', 'O')
('Caucasians', 'Caucasian', 'NNPS', 'B-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('Filipinos', 'Filipinos', 'NNP', 'B-NP', 'O')
('(Prescott', '(Prescott', 'NNP', 'I-NP', 'O')
('et', 'et', 'FW', 'I-NP', 'O')
('al', 'al', 'FW', 'I-NP', 'O')
(',', ',', ',', 'O', 'O')
('2000;', '2000;', 'IN', 'B-PP', 'O')
('Schultz', 'Schultz', 'NNP', 'B-NP', 'O')
('et', 'et', 'FW', 'I-NP', 'O')
('al', 'al', 'FW', 'I-NP', 'O')
('.,', '.,', 'VBD', 'B-VP', 'O')
('2004).', '2004).', 'CD', 'B-NP', 'O')
In summary, our genotype analyses show a significant association of TGFA -T3827C with nonsyndromic CL/P.
('In', 'In', 'IN', 'B-PP', 'O')
('summary,', 'summary,', 'NN', 'B-NP', 'O')
('our', 'our', 'PRP$', 'B-NP', 'O')
('genotype', 'genotype', 'NN', 'I-NP', 'O')
('analyses', 'analysis', 'NNS', 'I-NP', 'O')
('show', 'show', 'VBP', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('significant', 'significant', 'JJ', 'I-NP', 'O')
('association', 'association', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('TGFA', 'TGFA', 'NN', 'B-NP', 'B-protein')
('-T3827C', '-T3827C', 'NN', 'I-NP', 'I-protein')
('with', 'with', 'IN', 'B-PP', 'O')
('nonsyndromic', 'nonsyndromic', 'JJ', 'B-NP', 'O')
('CL/P.', 'CL/P.', 'NN', 'I-NP', 'O')
However, TGFA -C3296T, MTHFR -C677T and IRF6 -G820A showed no statistical significance in their association with CL/P.
('However,', 'However,', 'NN', 'B-NP', 'O')
('TGFA', 'TGFA', 'NN', 'I-NP', 'O')
('-C3296T,', '-C3296T,', 'NN', 'I-NP', 'O')
('MTHFR', 'MTHFR', 'NN', 'I-NP', 'O')
('-C677T', '-C677T', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('IRF6', 'IRF6', 'NN', 'B-NP', 'B-protein')
('-G820A', '-G820A', 'NN', 'I-NP', 'O')
('showed', 'show', 'VBD', 'B-VP', 'O')
('no', 'no', 'DT', 'B-NP', 'O')
('statistical', 'statistical', 'JJ', 'I-NP', 'O')
('significance', 'significance', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('their', 'their', 'PRP$', 'B-NP', 'O')
('association', 'association', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('CL/P.', 'CL/P.', 'NN', 'B-NP', 'O')
These contradictory results are probably due to genetic heterogeneity, incomplete penetrance, limited sample sizes and different study designs.
('These', 'These', 'DT', 'B-NP', 'O')
('contradictory', 'contradictory', 'JJ', 'I-NP', 'O')
('results', 'result', 'NNS', 'I-NP', 'O')
('are', 'be', 'VBP', 'B-VP', 'O')
('probably', 'probably', 'RB', 'B-ADVP', 'O')
('due', 'due', 'JJ', 'B-ADJP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('genetic', 'genetic', 'JJ', 'B-NP', 'O')
('heterogeneity,', 'heterogeneity,', 'NN', 'I-NP', 'O')
('incomplete', 'incomplete', 'JJ', 'I-NP', 'O')
('penetrance,', 'penetrance,', 'NN', 'I-NP', 'O')
('limited', 'limited', 'JJ', 'I-NP', 'O')
('sample', 'sample', 'NN', 'I-NP', 'O')
('sizes', 'size', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('different', 'different', 'JJ', 'B-NP', 'O')
('study', 'study', 'NN', 'I-NP', 'O')
('designs.', 'designs.', 'NN', 'I-NP', 'O')
A meta-analysis in a wider range of patient groups with more complete clinical descriptions of affected individuals may be required to more completely characterize the association between genetic markers and nonsyndromic CL/P.
('A', 'A', 'DT', 'B-NP', 'O')
('meta-analysis', 'meta-analysis', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('wider', 'wide', 'JJR', 'I-NP', 'O')
('range', 'range', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('patient', 'patient', 'NN', 'B-NP', 'O')
('groups', 'group', 'NNS', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('more', 'more', 'RBR', 'B-NP', 'O')
('complete', 'complete', 'JJ', 'I-NP', 'O')
('clinical', 'clinical', 'JJ', 'I-NP', 'O')
('descriptions', 'description', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('affected', 'affect', 'VBN', 'B-NP', 'O')
('individuals', 'individual', 'NNS', 'I-NP', 'O')
('may', 'may', 'MD', 'B-VP', 'O')
('be', 'be', 'VB', 'I-VP', 'O')
('required', 'require', 'VBN', 'I-VP', 'O')
('to', 'to', 'TO', 'I-VP', 'O')
('more', 'more', 'RBR', 'I-VP', 'O')
('completely', 'completely', 'RB', 'I-VP', 'O')
('characterize', 'characterize', 'VB', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('association', 'association', 'NN', 'I-NP', 'O')
('between', 'between', 'IN', 'B-PP', 'O')
('genetic', 'genetic', 'JJ', 'B-NP', 'O')
('markers', 'marker', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('nonsyndromic', 'nonsyndromic', 'JJ', 'B-NP', 'O')
('CL/P.', 'CL/P.', 'NN', 'I-NP', 'O')
